ONCY / Oncolytics Biotech Inc. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2025 Commission File Number 001-38512 Oncolytics B

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2025 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal execu

Oncolytics Biotech® Highlights Strong Efficacy and Translational Data in Metastatic Colorectal Cancer; Will Advance Regulatory Pathway Discussions In KRAS mutant 2L mCRC, pelareorep delivers prolonged survival benefit with a median PFS and median OS

Oncolytics Biotech® Highlights Strong Efficacy and Translational Data in Metastatic Colorectal Cancer; Will Advance Regulatory Pathway Discussions In KRAS mutant 2L mCRC, pelareorep delivers prolonged survival benefit with a median PFS and median OS approximately 2.

Oncolytics Biotech® Provides Updated Clinical Safety Data for Pelareorep, Including Across Multiple Gastrointestinal Tumors Data continue to demonstrate a favorable safety profile for pelareorep across multiple indications and in combination with mul

Oncolytics Biotech® Provides Updated Clinical Safety Data for Pelareorep, Including Across Multiple Gastrointestinal Tumors Data continue to demonstrate a favorable safety profile for pelareorep across multiple indications and in combination with multiple treatments Updated clinical data now account for over 300 gastrointestinal cancer patients, including patients from the GOBLET study, demonstrating pelareorep’s potential as a platform therapy Intravenously administered pelareorep continues to show clinical benefit SAN DIEGO, CA, September 2, 2025 – Oncolytics Biotech® Inc.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2025 Commission File Number 001-38512 Oncolytics B

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2025 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal execu

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2025 Commission File Number 001-38512 Oncolytics Biot

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2025 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executiv

Oncolytics Biotech® Announces Upcoming Investor Conferences in September

Oncolytics Biotech® Announces Upcoming Investor Conferences in September SAN DIEGO, CA, August 28, 2025 - Oncolytics Biotech® Inc.

Security Type

Calculation of Filing Fee Tables F-3 ONCOLYTICS BIOTECH INC Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward Newly Registered Securities Equity Common Shares 457(o) Other Subscription Receipts 457(o) Other Warrants 457(o) Other Units 457(o) Fees to be Paid 1 Unallocated (Universal) Shelf 457(o) $ 150,000,000.

As filed with the U.S. Securities and Exchange Commission on August 22, 2025.

As filed with the U.S. Securities and Exchange Commission on August 22, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Oncolytics Biotech Inc. (Exact name of registrant as specified in its charter) Alberta (State or other jurisdiction of incorporation or organization) 26-3847449 (I

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2025 Commission File Number 001-38512 Oncolytics Biot

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2025 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executiv

Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders

Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders SAN DIEGO, CA, August 11, 2025 - Oncolytics Biotech® Inc.

FORM 52‑109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE

FORM 52‑109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Jared Kelly, CEO of Oncolytics Biotech Inc.

FORM 52‑109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE

FORM 52‑109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Kirk Look, CFO of Oncolytics Biotech Inc.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2025 Commission File Number 001-38512 Oncolytics Biot

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2025 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executiv

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2025 Commission File Number 001-38512 Oncolytics Biot

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2025 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant’s name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executiv

MANAGEMENT'S DISCUSSION & ANALYSIS June 30, 2025

MANAGEMENT'S DISCUSSION & ANALYSIS June 30, 2025 August 7, 2025 MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This discussion and analysis should be read in conjunction with our unaudited condensed interim consolidated financial statements and notes thereto as at and for the three and six months ended June 30, 2025, and should also be read in conjunction with the audited consolidated financial statements and Management's Discussion and Analysis of Financial Condition and Results of Operations ("MD&A") contained in our annual report for the year ended December 31, 2024.

ONCOLYTICS BIOTECH INC. CONDENSED INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (in thousands of Canadian dollars, except share amounts) As at June 30, 2025 December 31, 2024 Assets Current assets Cash and cash equivalents (note 4) $ 14,626 $

Condensed Interim Consolidated Financial Statements (unaudited) Oncolytics Biotech® Inc.

Oncolytics Biotech® Announces Voluntary Delisting from the Toronto Stock Exchange

Oncolytics Biotech® Announces Voluntary Delisting from the Toronto Stock Exchange SAN DIEGO, CA, August 8, 2025 – Oncolytics Biotech® Inc.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2025 Commission File Number 000-38512 Oncolytics Biot

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2025 Commission File Number 000-38512 Oncolytics Biotech Inc. (Translation of registrant’s name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executiv

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2025 Commission File Number 001-38512 Oncolytics Biot

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2025 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executiv

Oncolytics Biotech® Reports Second Quarter Financial Results and Details Clinical Program Plans for Pelareorep Key opinion leader event and pancreatic cancer clinical data validate decision to engage with regulators on plans for a registration-enabli

Oncolytics Biotech® Reports Second Quarter Financial Results and Details Clinical Program Plans for Pelareorep Key opinion leader event and pancreatic cancer clinical data validate decision to engage with regulators on plans for a registration-enabling study New members of the management team bring expertise in progressing clinical programs and executing successful biotech transactions Translational data further elucidate pelareorep’s mechanism of action and ability to prime the tumor microenvironment for treatment Commitment to limiting dilution evidenced by termination of At-the-Market and Equity Line of Credit facilities SAN DIEGO, CA, August 8, 2025 – Oncolytics Biotech® Inc.

Oncolytics Biotech® Announces Upcoming Annual General Meeting and Second Quarter Financial Results The management team will provide a brief corporate update after the formal portion of the shareholder meeting

Oncolytics Biotech® Announces Upcoming Annual General Meeting and Second Quarter Financial Results The management team will provide a brief corporate update after the formal portion of the shareholder meeting SAN DIEGO, CA and CALGARY, AB, August 5, 2025 - Oncolytics Biotech® Inc.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2025 Commission File Number 001-38512 Oncolytics Biot

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2025 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executiv

Oncolytics Biotech® to Engage FDA for Potential Registration-Enabled Study in First-Line Pancreatic Cancer with Goal to Launch Trial Activities by Year-End Clear regulatory path and strong survival data in first-line metastatic pancreatic ductal aden

Oncolytics Biotech® to Engage FDA for Potential Registration-Enabled Study in First-Line Pancreatic Cancer with Goal to Launch Trial Activities by Year-End Clear regulatory path and strong survival data in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC) support accelerated strategy to drive shareholder value and partnership opportunities SAN DIEGO, CA and CALGARY, AB, July 29, 2025 – Oncolytics Biotech® Inc.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2025 Commission File Number 001-38512 Oncolytics Biotec

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2025 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executive

Key Opinion Leader Event Highlights Pelareorep’s Compelling Pancreatic and Gastrointestinal Data And Future Potential

Key Opinion Leader Event Highlights Pelareorep’s Compelling Pancreatic and Gastrointestinal Data And Future Potential SAN DIEGO, CA and CALGARY, AB, July 23, 2025 – Oncolytics Biotech® Inc.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2025 Commission File Number 001-38512 Oncolytics Biotec

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2025 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executive

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2025 Commission File Number 001-38512 Oncolytics Biotec

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2025 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executive

Oncolytics Biotech® Regains Compliance with Nasdaq Trading Rules

Oncolytics Biotech® Regains Compliance with Nasdaq Trading Rules SAN DIEGO, CA and CALGARY, AB, July 22, 2025 – Oncolytics Biotech® Inc.

Oncolytics Biotech® Presents Aggregated Translational Data Providing Evidence of Pelareorep’s Effectiveness Across Multiple Tumor Types Integrated biomarker analyses confirm viral replication, interferon signaling, and a surge in tumor-infiltrating l

Oncolytics Biotech® Presents Aggregated Translational Data Providing Evidence of Pelareorep’s Effectiveness Across Multiple Tumor Types Integrated biomarker analyses confirm viral replication, interferon signaling, and a surge in tumor-infiltrating lymphocytes after pelareorep treatment Cross-study data show pelareorep increases PD-L1 expression and boosts cytotoxic T-cell activity, priming resistant tumors for checkpoint inhibitors Results reinforce pelareorep’s ability to turn cold tumors hot, paving the way for registration-enabling trials SAN DIEGO, CA and CALGARY, AB, July 16, 2025 – Oncolytics Biotech® Inc.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2025 Commission File Number 001-38512 Oncolytics Biotec

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2025 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executive

Oncolytics Biotech® to Host Key Opinion Leader Discussion Focusing on Pancreatic and Gastrointestinal Cancers KOL webinar to take place on July 22, 2025, at 1:00 p.m. ET

Oncolytics Biotech® to Host Key Opinion Leader Discussion Focusing on Pancreatic and Gastrointestinal Cancers KOL webinar to take place on July 22, 2025, at 1:00 p.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2025 Commission File Number 001-38512 Oncolytics Biotec

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2025 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executive

NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON AUGUST 8, 2025 - AND - MANAGEMENT INFORMATION CIRCULAR June 18, 2025

NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON AUGUST 8, 2025 - AND - MANAGEMENT INFORMATION CIRCULAR June 18, 2025 June 18, 2025 Dear Shareholder: Important Notice regarding Participation in the Annual General Meeting of Shareholders on August 8, 2025 Oncolytics Biotech Inc.

Oncolytics Biotech® Highlights Transformative Pelareorep Survival Data in Multiple Tumors and Commitment to Registration-Enabling Studies Comparison with multiple landmark first-line metastatic pancreatic ductal adenocarcinoma studies substantiates s

Oncolytics Biotech® Highlights Transformative Pelareorep Survival Data in Multiple Tumors and Commitment to Registration-Enabling Studies Comparison with multiple landmark first-line metastatic pancreatic ductal adenocarcinoma studies substantiates strong two-year survival benefit of 21.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2025 Commission File Number 001-38512 Oncolytics Biotec

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2025 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executive

Oncolytics Biotech Inc. (the “Corporation”) Annual General Meeting August 8, 2025 at 10:00 a.m. ET via live audio webcast at https://virtual-meetings.tsxtrust.com/1824 password: onc2025 (the “Meeting”) Proxy Voting – Guidelines and Conditions 1. THIS

Oncolytics Biotech Inc. (the “Corporation”) Annual General Meeting August 8, 2025 at 10:00 a.m. ET via live audio webcast at https://virtual-meetings.tsxtrust.com/1824 password: onc2025 (the “Meeting”) Proxy Voting – Guidelines and Conditions 1. THIS PROXY IS SOLICITED BY OR ON BEHALF OF THE MANAGEMENT OF THE CORPORATION. 2. THIS PROXY SHOULD BE READ IN CONJUNCTION WITH THE MEETING MATERIALS PRIOR

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2025 Commission File Number 001-38512 Oncolytics Biotec

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2025 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant’s name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executive

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2025 Commission File Number 001-38512 Oncolytics Biotec

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2025 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executive

Oncolytics Biotech® Appoints Former Ambrx Executive as Chief Business Officer to Drive Business Development Strategy

Oncolytics Biotech® Appoints Former Ambrx Executive as Chief Business Officer to Drive Business Development Strategy SAN DIEGO, CA and CALGARY, AB, June 30, 2025 – Oncolytics Biotech® Inc.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2025 Commission File Number 001-38512 Oncolytics Biotec

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2025 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executive

Oncolytics Biotech® Names New CEO to Accelerate Momentum in Immunotherapy Programs

Oncolytics Biotech® Names New CEO to Accelerate Momentum in Immunotherapy Programs SAN DIEGO, CA and CALGARY, AB, June 11, 2025 – Oncolytics Biotech® Inc.

Oncolytics Biotech® to Present New Clinical Trial Data at ASCO Showing Pelareorep’s Unique Immune Activation Capabilities Pelareorep initiates a pro-inflammatory tumor microenvironment (TME) and induces innate and adaptive immune responses New analys

Oncolytics Biotech® to Present New Clinical Trial Data at ASCO Showing Pelareorep’s Unique Immune Activation Capabilities Pelareorep initiates a pro-inflammatory tumor microenvironment (TME) and induces innate and adaptive immune responses New analyses confirm that pelareorep primes the TME to allow circulating tumor-infiltrating lymphocytes (TILs) in the blood to attack tumors Pre-existing TIL clones in plasma may correlate positively with tumor shrinkage in pancreatic cancer SAN DIEGO, CA and CALGARY, AB, May 23, 2025 – Oncolytics Biotech® Inc.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2025 Commission File Number 001-38512 Oncolytics Biotech

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2025 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executive o

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2025 Commission File Number 001-38512 Oncolytics Biotech

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2025 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executive o

FORM 52‑109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE

FORM 52‑109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Wayne Pisano, Interim CEO of Oncolytics Biotech Inc.

Oncolytics Biotech® Reports First Quarter Financial Results and Highlights Clinical Momentum American Society of Clinical Oncology (ASCO) GI Symposium data underscores pelareorep’s clinical benefit in anal and pancreatic cancers Pelareorep featured i

Oncolytics Biotech® Reports First Quarter Financial Results and Highlights Clinical Momentum American Society of Clinical Oncology (ASCO) GI Symposium data underscores pelareorep’s clinical benefit in anal and pancreatic cancers Pelareorep featured in Key Opinion Leader event on oncolytic immunotherapies in breast and pancreatic cancers Poster on pelareorep’s stimulation of adaptive and innate immunity to be shared at ASCO Annual Meeting Conference call and webcast today at 4:30 p.

MANAGEMENT'S DISCUSSION & ANALYSIS March 31, 2025

MANAGEMENT'S DISCUSSION & ANALYSIS March 31, 2025 May 14, 2025 MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This discussion and analysis should be read in conjunction with our unaudited condensed interim consolidated financial statements and notes thereto as at and for the three months ended March 31, 2025, and should also be read in conjunction with the audited consolidated financial statements and Management's Discussion and Analysis of Financial Condition and Results of Operations ("MD&A") contained in our annual report for the year ended December 31, 2024.

FORM 52‑109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE

FORM 52‑109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Kirk Look, CFO of Oncolytics Biotech Inc.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2025 Commission File Number 001-38512 Oncolytics Biotech

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2025 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant’s name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executive o

ONCOLYTICS BIOTECH INC. CONDENSED INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (in thousands of Canadian dollars, except share amounts) As at March 31, 2025 December 31, 2024 Assets Current assets Cash and cash equivalents (note 4) $ 15,303

Condensed Interim Consolidated Financial Statements (unaudited) Oncolytics Biotech® Inc.

Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights Conference call and webcast to take place on Wednesday, May 14, 2025, at 4:30 p.m. ET

Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights Conference call and webcast to take place on Wednesday, May 14, 2025, at 4:30 p.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2025 Commission File Number 001-38512 Oncolytics Biotech

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2025 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executive o

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2025 Commission File Number 001-38512 Oncolytics Biote

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2025 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executive

Oncolytics Biotech® to Showcase New Pancreatic Cancer Data at ASCO Highlighting Pelareorep’s Tumor-Fighting Mechanism of Action ASCO data expected to highlight how pelareorep activates immune responses in pancreatic cancer patients Ongoing updates su

Oncolytics Biotech® to Showcase New Pancreatic Cancer Data at ASCO Highlighting Pelareorep’s Tumor-Fighting Mechanism of Action ASCO data expected to highlight how pelareorep activates immune responses in pancreatic cancer patients Ongoing updates support potential of pelareorep combination therapies in one of the deadliest and hardest-to-treat cancers SAN DIEGO, CA and CALGARY, AB, April 24, 2025 – Oncolytics Biotech® Inc.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2025 Commission File Number 001-38512 Oncolytics Biote

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2025 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executive

Oncolytics Biotech® Funds Pelareorep’s Ongoing Clinical Development with a Share Purchase Agreement in Partnership with Alumni Capital

Oncolytics Biotech® Funds Pelareorep’s Ongoing Clinical Development with a Share Purchase Agreement in Partnership with Alumni Capital SAN DIEGO, CA and CALGARY, AB, April 10, 2025 – Oncolytics Biotech® Inc.

PURCHASE AGREEMENT

Exhibit 99.1 PURCHASE AGREEMENT PURCHASE AGREEMENT (this “Agreement”), dated as of April 10, 2025 (the “Execution Date”), is entered into by and between ONCOLYTICS BIOTECH INC., a company incorporated under the Business Corporations Act (Alberta) (the “Company”), and ALUMNI CAPITAL LP, a Delaware limited partnership (the “Investor”). RECITALS WHEREAS, subject to the terms and conditions set forth

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2025 Commission File Number 000-38512 Oncolytics Biote

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2025 Commission File Number 000-38512 Oncolytics Biotech Inc. (Translation of registrant’s name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executive

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2025 Commission File Number 001-38512 Oncolytics Biote

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2025 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executive

Oncolytics Biotech® and Pelareorep Discussed During Recent H.C. Wainwright Key Opinion Leader Event on Oncolytic Immunotherapies in Breast and Pancreatic Cancers

Oncolytics Biotech® and Pelareorep Discussed During Recent H.C. Wainwright Key Opinion Leader Event on Oncolytic Immunotherapies in Breast and Pancreatic Cancers SAN DIEGO, CA and CALGARY, AB, April 10, 2025 – Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, was discussed by field-leading key opinion leaders (KOLs) dur

Common Shares

Filed pursuant to General Instruction II.L of Form F-10 File No. 333-281009 PROSPECTUS SUPPLEMENT (To Base Shelf Prospectus dated July 19, 2024) US$20,800,000 Common Shares This prospectus supplement (the “Prospectus Supplement”) of Oncolytics Biotech Inc. (“Oncolytics” or the “Corporation”), together with the accompanying short form base shelf prospectus dated July 19, 2024 (the “Prospectus”), qu

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

EXHIBIT 15.2 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in the following Registration Statements: 1.Form S-8 nos. 333-171625, 333-205708 and 333-279926 2.Form F-10 no. 333-281009 of Oncolytics Biotech Inc. (the “Company”) of our reports dated March 6, 2025, with respect to the consolidated statements of financial position as at December 31

LIST OF SUBSIDIARIES Name Jurisdiction Oncolytics Biotech (Barbados) Inc. Barbados Oncolytics Biotech (US) Inc. Delaware

EXHIBIT 8.0 LIST OF SUBSIDIARIES 2024 Name Jurisdiction Oncolytics Biotech (Barbados) Inc. Barbados Oncolytics Biotech (US) Inc. Delaware

Oncolytics Biotech® Reports Highlights and Financial Results for Q4 and Year-End 2024 BRACELET-1 results in HR+/HER2- metastatic breast cancer surpass expectations, providing meaningful data for a registration-enabling study Data from GOBLET in pancr

Oncolytics Biotech® Reports Highlights and Financial Results for Q4 and Year-End 2024 BRACELET-1 results in HR+/HER2- metastatic breast cancer surpass expectations, providing meaningful data for a registration-enabling study Data from GOBLET in pancreatic and anal carcinoma support continued development of pelareorep in these indications, with combination studies ongoing Cash position of $15.

Date: March 7, 2025 /s/Wayne Pisano Wayne Pisano Interim Chief Executive Officer Interim Principal Executive Officer

EXHIBIT 12.1 CERTIFICATION I, Wayne Pisano, certify that: 1.I have reviewed this annual report on Form 20-F of Oncolytics Biotech Inc.; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect t

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March 2025 Commission File Number 001-38512 Oncolytics Biote

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March 2025 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executive

Date: March 7, 2025 /s/Kirk Look Kirk Look, CA Chief Financial Officer Principal Accounting and Financial Officer

EXHIBIT 12.2 CERTIFICATION I, Kirk Look, certify that: 1.I have reviewed this annual report on Form 20-F of Oncolytics Biotech Inc.; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to t

MANAGEMENT'S DISCUSSION & ANALYSIS

MANAGEMENT'S DISCUSSION & ANALYSIS 2024 March 6, 2025 MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS BASIS OF PRESENTATION Our Management's Discussion and Analysis of Financial Condition and Results of Operations ("MD&A") should be read in conjunction with our audited consolidated financial statements and notes thereto as at and for the year ended December 31, 2024, which have been prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB").

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For fiscal year ended December 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 19

CERTIFICATION PURSUANT TO 18 U.S.C. §1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

EXHIBIT 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. §1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the annual report of Oncolytics Biotech Inc. (the “Company”) on Form 20-F for the fiscal year ended December 31, 2024, as filed with the Securities and Exchange Commission on the date here of (the “Report”), I, Kirk Look, Chief Financial Officer of the Com

DESCRIPTION OF RIGHTS OF SECURITIES REGISTERED UNDER SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934

EXHIBIT 2.1 DESCRIPTION OF RIGHTS OF SECURITIES REGISTERED UNDER SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Our authorized capital consists of an unlimited number of Common Shares. The following is a summary of the provisions attached to our Common Shares: The holders of our Common Shares are entitled to one vote per share at meetings of shareholders, to receive such dividends as declared b

CERTIFICATION PURSUANT TO 18 U.S.C. §1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

EXHIBIT 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. §1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the annual report of Oncolytics Biotech Inc. (the “Company”) on Form 20-F for the fiscal year ended December 31, 2024, as filed with the Securities and Exchange Commission on the date here of (the “Report”), I, Wayne Pisano, Interim Chief Executive Officer

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2025 Commission File Number 001-38512 Oncolytics Bi

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2025 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal execut

Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights Conference call and webcast to take place on Friday, March 7, 2025, at 8:30 a.m. ET

Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights Conference call and webcast to take place on Friday, March 7, 2025, at 8:30 a.

Oncolytics Biotech® Advances Key Pancreatic and Anal Cancer Trials, Strengthening Pipeline in 2025 Regulatory progress in pancreatic cancer and recent clinical data presentations in two hard-to-treat GI cancers, coupled with strong efficacy signals i

Oncolytics Biotech® Advances Key Pancreatic and Anal Cancer Trials, Strengthening Pipeline in 2025 Regulatory progress in pancreatic cancer and recent clinical data presentations in two hard-to-treat GI cancers, coupled with strong efficacy signals in breast cancer, highlight pelareorep’s potential impact across a range of tumors SAN DIEGO, CA and CALGARY, AB, February 19, 2025 – Oncolytics Biotech® Inc.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2025 Commission File Number 001-38512 Oncolytics Bi

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2025 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal execut

Oncolytics Biotech® Strengthens Its Pipeline in 2025 with Key Pancreatic and Anal Cancer Advances in Addition to Metastatic Breast Cancer Recent clinical data presentations in these two hard-to-treat GI cancers, coupled with strong efficacy signals i

Oncolytics Biotech® Strengthens Its Pipeline in 2025 with Key Pancreatic and Anal Cancer Advances in Addition to Metastatic Breast Cancer Recent clinical data presentations in these two hard-to-treat GI cancers, coupled with strong efficacy signals in breast cancer, demonstrate the potential of pelareorep across very different tumor types SAN DIEGO, CA and CALGARY, AB, February 18, 2025 – Oncolytics Biotech® Inc.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2025 Commission File Number 001-38512 Oncolytics Bi

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2025 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal execut

Oncolytics Biotech® Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

Oncolytics Biotech® Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency SAN DIEGO, CA and CALGARY, AB, February 14, 2025 – Oncolytics Biotech® Inc.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2025 Commission File Number 001-38512 Oncolytics Bi

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2025 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal execut

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2025 Commission File Number 001-38512 Oncolytics Bi

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2025 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal execut

Oncolytics Biotech® Announces Matt Coffey, Ph.D. Will Not Return to CEO Role Following Medical Leave of Absence Search for Chief Executive Officer to commence immediately

Oncolytics Biotech® Announces Matt Coffey, Ph.D. Will Not Return to CEO Role Following Medical Leave of Absence Search for Chief Executive Officer to commence immediately SAN DIEGO, CA and CALGARY, AB, February 7, 2025 – Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that Matt Coffey, Ph.D., President

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of January 2025 Commission File Number 001-38512 Oncolytics Bio

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of January 2025 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executi

Oncolytics Biotech® to Present Compelling New Efficacy and Safety Data in Anal and Pancreatic Cancers at 2025 ASCO GI Symposium Pelareorep combination therapy shows continued meaningful improvement over checkpoint inhibitors alone in anal cancer pati

Oncolytics Biotech® to Present Compelling New Efficacy and Safety Data in Anal and Pancreatic Cancers at 2025 ASCO GI Symposium Pelareorep combination therapy shows continued meaningful improvement over checkpoint inhibitors alone in anal cancer patients Pelareorep-based therapy demonstrates strong safety profile with new chemotherapy regimen in pancreatic cancer patients SAN DIEGO, CA and CALGARY, AB, January 22, 2025 – Oncolytics Biotech® Inc.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of January 2025 Commission File Number 001-38512 Oncolytics Bio

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of January 2025 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executi

Regulatory Approval Clears Path for Oncolytics Biotech® to Advance Promising Pancreatic Cancer Treatment, Following a Review of Safety Data New pancreatic cancer cohort moves forward with full enrollment of 30 patients in Stage 1

Regulatory Approval Clears Path for Oncolytics Biotech® to Advance Promising Pancreatic Cancer Treatment, Following a Review of Safety Data New pancreatic cancer cohort moves forward with full enrollment of 30 patients in Stage 1 SAN DIEGO, CA and CALGARY, AB, January 15, 2025 – Oncolytics Biotech® Inc.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2024 Commission File Number 001-38512 Oncolytics Bi

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2024 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal execut

Oncolytics Biotech® Highlights 2024 Achievements and Prepares for an Influential 2025 with Promising Breast and GI Cancer Data Promising BRACELET-1 results in HR+/HER2- metastatic breast cancer lay the foundation for potential registration-enabling s

Oncolytics Biotech® Highlights 2024 Achievements and Prepares for an Influential 2025 with Promising Breast and GI Cancer Data Promising BRACELET-1 results in HR+/HER2- metastatic breast cancer lay the foundation for potential registration-enabling study and accelerated approval Advancing gastrointestinal cancer pipeline underscores potential for additional registration-enabling studies SAN DIEGO, CA and CALGARY, AB, December 23, 2024 - Oncolytics Biotech® Inc.

Oncolytics Biotech® to Present Promising Pelareorep Data in Pancreatic and Anal Cancers at ASCO GI Symposium

Oncolytics Biotech® to Present Promising Pelareorep Data in Pancreatic and Anal Cancers at ASCO GI Symposium SAN DIEGO, CA and CALGARY, AB, December 18, 2024 – Oncolytics Biotech® Inc.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2024 Commission File Number 001-38512 Oncolytics Bi

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2024 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal execut

Oncolytics Biotech® Reports Completion of Initial Safety Phase Enrollment for GOBLET Trial’s New Pancreatic Cancer Cohort Early safety and tolerability results from six randomized patients support continued enrollment of pelareorep combined with modi

Oncolytics Biotech® Reports Completion of Initial Safety Phase Enrollment for GOBLET Trial’s New Pancreatic Cancer Cohort Early safety and tolerability results from six randomized patients support continued enrollment of pelareorep combined with modified FOLFIRINOX, with or without atezolizumab The study will begin with 30 patients, with an option to expand to an additional 34 participants SAN DIEGO, CA and CALGARY, AB, December 3, 2024 - Oncolytics Biotech® Inc.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2024 Commission File Number 001-38512 Oncolytics Bi

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2024 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal execut

FORM 52‑109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE

FORM 52‑109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Wayne Pisano, Interim CEO of Oncolytics Biotech Inc.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2024 Commission File Number 001-38512 Oncolytics Bi

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2024 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal execut

FORM 52‑109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE

FORM 52‑109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Kirk Look, CFO of Oncolytics Biotech Inc.

ONCOLYTICS BIOTECH INC. CONDENSED INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (in thousands of Canadian dollars, except share amounts) As at September 30, 2024 December 31, 2023 Assets Current assets Cash and cash equivalents (note 4) $ 19,

Condensed Interim Consolidated Financial Statements (unaudited) Oncolytics Biotech® Inc.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2024 Commission File Number 001-38512 Oncolytics Bi

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2024 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal execut

MANAGEMENT'S DISCUSSION & ANALYSIS September 30, 2024

MANAGEMENT'S DISCUSSION & ANALYSIS September 30, 2024 November 9, 2024 MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This discussion and analysis should be read in conjunction with our unaudited condensed interim consolidated financial statements and notes thereto as at and for the three and nine months ended September 30, 2024, and should also be read in conjunction with the audited consolidated financial statements and Management's Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) contained in our annual report for the year ended December 31, 2023.

Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational Highlights Conference call and webcast to take place on Tuesday, November 12, 2024, at 8:30 a.m. ET

Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational Highlights Conference call and webcast to take place on Tuesday, November 12, 2024, at 8:30 a.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2024 Commission File Number 001-38512 Oncolytics Bi

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2024 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant’s name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal execut

Oncolytics Biotech® Reports Third Quarter 2024 Financial Results and Operational Highlights BRACELET-1 data showing impressive overall survival benefit in HR+/HER2- metastatic breast cancer affirms pelareorep + paclitaxel combination should be evalua

Oncolytics Biotech® Reports Third Quarter 2024 Financial Results and Operational Highlights BRACELET-1 data showing impressive overall survival benefit in HR+/HER2- metastatic breast cancer affirms pelareorep + paclitaxel combination should be evaluated in a registrational study Upcoming GOBLET milestones include updated efficacy data from anal cancer cohort and safety run-in data from the modified FOLFIRINOX pancreatic cancer cohort Cash position of $19.

Oncolytics Biotech® Announces Key Progress and Upcoming Studies for Breast and Pancreatic Cancer Treatments, Prepares for FDA Accelerated Approval Path Recent clinical efficacy results from the BRACELET-1 trial in HR+/HER2- breast cancer pave the way

Oncolytics Biotech® Announces Key Progress and Upcoming Studies for Breast and Pancreatic Cancer Treatments, Prepares for FDA Accelerated Approval Path Recent clinical efficacy results from the BRACELET-1 trial in HR+/HER2- breast cancer pave the way for a clinical study designed to support an accelerated approval Key milestones in gastrointestinal cancer clinical trials expected in 2025, with potential for new registration-enabling studies SAN DIEGO, CA and CALGARY, AB, October 4, 2024 - Oncolytics Biotech® Inc.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of October 2024 Commission File Number 001-38512 Oncolytics Bio

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of October 2024 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executi

Oncolytics Biotech® Reports Favorable Results for BRACELET-1 Breast Cancer Study Reinforcing Path to Funding of a Registration-Enabling Study •Overall survival (OS) results from BRACELET-1 corroborate results of previous randomized IND-213 breast can

Oncolytics Biotech® Reports Favorable Results for BRACELET-1 Breast Cancer Study Reinforcing Path to Funding of a Registration-Enabling Study •Overall survival (OS) results from BRACELET-1 corroborate results of previous randomized IND-213 breast cancer study •Together, these two studies support the compelling potential of pelareorep-based combination therapy to benefit patients with advanced or m

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2024 Commission File Number 001-38512 Oncolytics B

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2024 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal execu

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2024 Commission File Number 001-38512 Oncolytics B

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2024 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal execu

Oncolytics Biotech® to Participate in Fireside Chats at Two Investment Conferences in September

Oncolytics Biotech® to Participate in Fireside Chats at Two Investment Conferences in September SAN DIEGO, CA and CALGARY, AB, September 6, 2024 - Oncolytics Biotech® Inc.

The date of this Prospectus Supplement is August 2, 2024. TABLE OF CONTENTS Prospectus Supplement

Filed pursuant to General Instruction II.L of Form F-10 File No. 333-281009 PROSPECTUS SUPPLEMENT (To Base Shelf Prospectus dated July 19, 2024) 64,035 Common Shares We are hereby qualifying for distribution the issuance of: (i) up to 64,035 common shares (“Common Shares”) of the Corporation, issuable from time to time, on exercise of up to 64,035 Common Share purchase warrants issued by us on Aug

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2024 Commission File Number 000-38512 Oncolytics Biot

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2024 Commission File Number 000-38512 Oncolytics Biotech Inc. (Translation of registrant’s name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executiv

The date of this Prospectus Supplement is August 2, 2024. TABLE OF CONTENTS Prospectus Supplement

Filed pursuant to General Instruction II.L of Form F-10 File No. 333-281009 PROSPECTUS SUPPLEMENT (To Base Shelf Prospectus dated July 19, 2024) Up to US$50,000,000 Common Shares Oncolytics Biotech Inc. (“Oncolytics” or the “Corporation”) has entered into an equity distribution agreement dated August 2, 2024 (the “Equity Distribution Agreement”) with Cantor Fitzgerald & Co. (“Cantor”) relating to

Oncolytics Biotech® to Participate in a Fireside Chat at Canaccord Genuity’s 44th Annual Growth Conference

Oncolytics Biotech® to Participate in a Fireside Chat at Canaccord Genuity’s 44th Annual Growth Conference SAN DIEGO, CA and CALGARY, AB, August 2, 2024 - Oncolytics Biotech® Inc.

ONCOLYTICS BIOTECH INC. equity distribution AGREEMENT

Exhibit 99.1 ONCOLYTICS BIOTECH INC. US$50,000,000 equity distribution AGREEMENT August 2, 2024 Cantor Fitzgerald & Co. 110 East 59th Street New York, New York 10022 Ladies and Gentlemen: Oncolytics Biotech Inc., a company incorporated under the Business Corporations Act (Alberta) (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (“CF&Co”), as follows: 1.     

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2024 Commission File Number 001-38512 Oncolytics Biot

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2024 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executiv

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2024 Commission File Number 001-38512 Oncolytics Biot

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2024 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executiv

FORM 52‑109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE

FORM 52‑109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Kirk Look, CFO of Oncolytics Biotech Inc.

FORM 52‑109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE

FORM 52‑109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Wayne Pisano, Interim CEO of Oncolytics Biotech Inc.

ONCOLYTICS BIOTECH INC. CONDENSED INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (in thousands of Canadian dollars, except share amounts) As at June 30, 2024 December 31, 2023 Assets Current assets Cash and cash equivalents (note 4) $ 24,850 $

Condensed Interim Consolidated Financial Statements (unaudited) Oncolytics Biotech® Inc.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2024 Commission File Number 001-38512 Oncolytics Biot

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2024 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant’s name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executiv

Oncolytics Biotech® Reports Second Quarter 2024 Financial Results and Operational Highlights Received productive feedback from Type C meeting with the FDA for the planned registration-enabling trial for pelareorep in HR+/HER2- metastatic breast cance

Oncolytics Biotech® Reports Second Quarter 2024 Financial Results and Operational Highlights Received productive feedback from Type C meeting with the FDA for the planned registration-enabling trial for pelareorep in HR+/HER2- metastatic breast cancer On track to report overall survival results from randomized BRACELET-1 breast cancer study in H2 2024 Dosed first patient in new GOBLET study pancreatic cancer cohort; supported by funding from PanCAN Entered into collaboration with GCAR for inclusion of pelareorep in adaptive registration-enabling pancreatic cancer trial Cash position of $24.

MANAGEMENT'S DISCUSSION & ANALYSIS June 30, 2024

MANAGEMENT'S DISCUSSION & ANALYSIS June 30, 2024 August 1, 2024 MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This discussion and analysis should be read in conjunction with our unaudited condensed interim consolidated financial statements and notes thereto as at and for the three and six months ended June 30, 2024, and should also be read in conjunction with the audited consolidated financial statements and Management's Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) contained in our annual report for the year ended December 31, 2023.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-X APPOINTMENT OF AGENT FOR SERVICE OF PROCESS AND UNDERTAKING

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-X APPOINTMENT OF AGENT FOR SERVICE OF PROCESS AND UNDERTAKING A. Name of issuer or person filing ("Filer"): Oncolytics Biotech Inc. B. (1) This is an (check one): x original filing for the Filer. ¨ amended filing for the Filer. (2) Check following box if you are filing the Form F-X in paper in accordance with Regulation

Calculation Of Filing Fee Tables Form F-10 (Form Type) Oncolytics Biotech Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities

Exhibit 107 Calculation Of Filing Fee Tables Form F-10 (Form Type) Oncolytics Biotech Inc.

As filed with the Securities and Exchange Commission on July 25, 2024

As filed with the Securities and Exchange Commission on July 25, 2024 Registration Statement No.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2024 Commission File Number 001-38512 Oncolytics Biotec

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2024 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executive

Oncolytics Biotech® to Host Conference Call to Discuss Second Quarter Financial Results and Recent Operational Highlights Conference call and webcast to take place on Thursday, August 1, 2024, at 4:30 p.m. ET

Oncolytics Biotech® to Host Conference Call to Discuss Second Quarter Financial Results and Recent Operational Highlights Conference call and webcast to take place on Thursday, August 1, 2024, at 4:30 p.

Oncolytics Biotech® Announces Productive FDA Type C Meeting on its Metastatic Breast Cancer Program Clear path forward on key elements of the planned potential registration-enabling trial in HR+/HER2- metastatic breast cancer On track to report overa

Oncolytics Biotech® Announces Productive FDA Type C Meeting on its Metastatic Breast Cancer Program Clear path forward on key elements of the planned potential registration-enabling trial in HR+/HER2- metastatic breast cancer On track to report overall survival results from the randomized HR+/HER2- metastatic breast cancer BRACELET-1 trial in H2 2024 SAN DIEGO, CA, and CALGARY, AB, June 27, 2024 - Oncolytics Biotech® Inc.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2024 Commission File Number 001-38512 Oncolytics Biotec

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2024 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executive

Oncolytics Biotech® Announces President and Chief Executive Officer Dr. Matt Coffey to Take Medical Leave of Absence Wayne Pisano, Chair of Oncolytics’ Board of Directors, to serve as interim CEO Overall Survival data from BRACELET-1 breast cancer st

Oncolytics Biotech® Announces President and Chief Executive Officer Dr. Matt Coffey to Take Medical Leave of Absence Wayne Pisano, Chair of Oncolytics’ Board of Directors, to serve as interim CEO Overall Survival data from BRACELET-1 breast cancer study continues to be expected in H2 2024 Pelareorep combination therapy advancing towards registration-enabling study in pancreatic cancer SAN DIEGO, C

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2024 Commission File Number 001-38512 Oncolytics Biotec

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2024 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executive

Oncolytics Biotech® Doses First Patient in Study of Pelareorep/FOLFIRINOX Combination Therapy in Pancreatic Cancer Demonstrating pelareorep’s synergy with modified FOLFIRINOX +/- atezolizumab in pancreatic cancer could expand the number of patients i

Oncolytics Biotech® Doses First Patient in Study of Pelareorep/FOLFIRINOX Combination Therapy in Pancreatic Cancer Demonstrating pelareorep’s synergy with modified FOLFIRINOX +/- atezolizumab in pancreatic cancer could expand the number of patients it may benefit Funding for the study comes from the US$5 million Therapeutic Accelerator Award from PanCAN SAN DIEGO, CA, and CALGARY, AB, June 20, 2024 - Oncolytics Biotech® Inc.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2024 Commission File Number 001-38512 Oncolytics Biotec

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2024 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executive

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

As filed with the Securities and Exchange Commission on June 3, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Calculation of Filing Fee Tables Form S-8 (Form Type) Oncolytics Biotech Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Oncolytics Biotech Inc.

AMENDED AND RESTATED STOCK OPTION PLAN

Exhibit 4.1 AMENDED AND RESTATED STOCK OPTION PLAN 1. The Plan The Board of Directors of Oncolytics Biotech Inc. (the “Corporation”) has adopted this Stock Option Plan (the “Plan”) governing the issuance of Options (as defined herein) of the Corporation to Eligible Persons (as defined herein). 2. Purpose The purpose of this Plan is to advance the interests of the Corporation by encouraging the Dir

AMENDED AND RESTATED INCENTIVE SHARE AWARD PLAN

Exhibit 4.2 AMENDED AND RESTATED INCENTIVE SHARE AWARD PLAN The Board of Directors of Oncolytics Biotech Inc. (the “Corporation”) has adopted this Incentive Share Award Plan (the “Plan”) governing the issuance of: (i) Restricted Share Awards to Eligible Persons; and (ii) Performance Share Awards to Employees. 1. Purposes The principal purposes of the Plan are as follows: (a) to retain and attract

Oncolytics Biotech® ASCO Abstracts Highlight Pelareorep’s Potential in Pancreatic Cancer and Immunotherapeutic Mechanism of Action Trial-in-progress abstract highlights new cohort that could expand the company’s pancreatic cancer program Pelareorep’s

Oncolytics Biotech® ASCO Abstracts Highlight Pelareorep’s Potential in Pancreatic Cancer and Immunotherapeutic Mechanism of Action Trial-in-progress abstract highlights new cohort that could expand the company’s pancreatic cancer program Pelareorep’s ability to expand TILs highlights its immunotherapeutic mechanism of action and potential as a backbone immunotherapy for multiple indications SAN DIEGO, CA and CALGARY, AB, May 24, 2024 – Oncolytics Biotech® Inc.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2024 Commission File Number 001-38512 Oncolytics Biotech

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2024 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executive o

Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders

Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders SAN DIEGO, CA and CALGARY, AB, May 16, 2024 - Oncolytics Biotech® Inc.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2024 Commission File Number 001-38512 Oncolytics Biotech

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2024 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executive o

Oncolytics Biotech® Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Anticipated Pancreatic Cancer Trial Anticipated evaluation to include combination therapy featuring treatment regimen of checkpoint inhibition and chemot

Oncolytics Biotech® Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Anticipated Pancreatic Cancer Trial Anticipated evaluation to include combination therapy featuring treatment regimen of checkpoint inhibition and chemotherapy utilized in cohort 1 of the GOBLET study GCAR is launching a new master protocol for pancreatic cancer with the intent to create a registration-enabling pathway for investigational therapies Innovative adaptive design could accelerate registrational study timeline and provide substantial cost savings compared to traditional trial designs SAN DIEGO, CA and CALGARY, AB, May 15, 2024 – Oncolytics Biotech® Inc.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2024 Commission File Number 001-38512 Oncolytics Biotech

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2024 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executive o

Oncolytics Biotech® Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer US$5 million PanCAN grant provides important support for the fifth cohort of the GOBLET

Oncolytics Biotech® Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer US$5 million PanCAN grant provides important support for the fifth cohort of the GOBLET study Study of modified FOLFIRINOX/pelareorep/atezolizumab (Tecentriq®) combination expands existing pancreatic cancer program First patient expected to be enrolled in Q2 2024 SAN DIEGO, CA, and CALGARY, AB, May 9, 2024 - Oncolytics Biotech® Inc.

FORM 52‑109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE

FORM 52‑109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Kirk Look, CFO of Oncolytics Biotech Inc.

MANAGEMENT'S DISCUSSION & ANALYSIS March 31, 2024

MANAGEMENT'S DISCUSSION & ANALYSIS March 31, 2024 May 9, 2024 MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This discussion and analysis should be read in conjunction with our unaudited condensed interim consolidated financial statements and notes thereto as at and for the three months ended March 31, 2024, and should also be read in conjunction with the audited consolidated financial statements and Management's Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) contained in our annual report for the year ended December 31, 2023.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2024 Commission File Number 001-38512 Oncolytics Biotech

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2024 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executive o

ONCOLYTICS BIOTECH INC. CONDENSED INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (in thousands of Canadian dollars, except share amounts) As at March 31, 2024 December 31, 2023 Assets Current assets Cash and cash equivalents (note 4) $ 29,603

Condensed Interim Consolidated Financial Statements (unaudited) Oncolytics Biotech® Inc.

Oncolytics Biotech® Reports First Quarter 2024 Financial Results and Operational Highlights Pelareorep advancing to registration-enabling studies Preparations underway for Type C meeting with the FDA to establish registrational pathway in HR+/HER2- m

Oncolytics Biotech® Reports First Quarter 2024 Financial Results and Operational Highlights Pelareorep advancing to registration-enabling studies Preparations underway for Type C meeting with the FDA to establish registrational pathway in HR+/HER2- metastatic breast cancer Overall survival data from BRACELET-1 breast cancer study expected in H2 2024 Cash position of $29.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2024 Commission File Number 001-38512 Oncolytics Biotech

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2024 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executive o

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2024 Commission File Number 001-38512 Oncolytics Biotech

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2024 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant’s name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executive o

FORM 52‑109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE

FORM 52‑109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Matthew Coffey, President and CEO of Oncolytics Biotech Inc.

Oncolytics Biotech® to Participate in a Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference

Oncolytics Biotech® to Participate in a Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference SAN DIEGO, CA and CALGARY, AB, May 8, 2024 - Oncolytics Biotech® Inc.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2024 Commission File Number 001-38512 Oncolytics Biotech

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2024 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executive o

Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights Conference call and webcast to take place on Thursday, May 9, 2024, at 4:30 p.m. ET

Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights Conference call and webcast to take place on Thursday, May 9, 2024, at 4:30 p.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2024 Commission File Number 001-38512 Oncolytics Biote

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2024 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executive

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2024 Commission File Number 001-38512 Oncolytics Biote

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2024 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executive

Oncolytics Biotech® Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meeting

Oncolytics Biotech® Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meeting SAN DIEGO, CA and CALGARY, AB, April 25, 2024 – Oncolytics Biotech® Inc.

NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON MAY 15, 2024 - AND - MANAGEMENT INFORMATION CIRCULAR MARCH 26, 2024

NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON MAY 15, 2024 - AND - MANAGEMENT INFORMATION CIRCULAR MARCH 26, 2024 March 26, 2024 Dear Shareholder: Important Notice regarding Participation in the Annual Meeting of Shareholders on May 15, 2024 Oncolytics Biotech Inc.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of April, 2024. Commission File Number 001-38512 Oncolytics

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of April, 2024. Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant’s name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal exec

At the discretion of the said proxyholders, upon any amendment or variation of the above matters or any other matter that may be properly brought before the Meeting or any adjournment or postponement thereof in such manner as such proxy, in such prox

At the discretion of the said proxyholders, upon any amendment or variation of the above matters or any other matter that may be properly brought before the Meeting or any adjournment or postponement thereof in such manner as such proxy, in such proxyholder's sole judgment, may determine.

Oncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA Requested for Q2 2024, the Type C meeting is to focus on planned registration-enabling trial in HR+/HER2-

Oncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA Requested for Q2 2024, the Type C meeting is to focus on planned registration-enabling trial in HR+/HER2- metastatic breast cancer Overall survival results from the randomized HR+/HER2- metastatic breast cancer BRACELET-1 trial expected in H2 2024 SAN DIEGO, CA and CALGARY, AB, April 11, 2024 - Oncolytics Biotech® Inc.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2024 Commission File Number 001-38512 Oncolytics Biote

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2024 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executive

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2024 Commission File Number 001-38512 Oncolytics Biote

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2024 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executive

Oncolytics Biotech® to Participate in a Panel Presentation at Canaccord Genuity’s Horizons in Oncology Virtual Conference

Oncolytics Biotech® to Participate in a Panel Presentation at Canaccord Genuity’s Horizons in Oncology Virtual Conference SAN DIEGO, CA and CALGARY, AB, April 2, 2024 - Oncolytics Biotech® Inc.

MANAGEMENT'S DISCUSSION & ANALYSIS

MANAGEMENT'S DISCUSSION & ANALYSIS 2023 March 7, 2024 MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS BASIS OF PRESENTATION Our Management's Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) should be read in conjunction with our audited consolidated financial statements and notes thereto as at and for the year ended December 31, 2023, which have been prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB").

CERTIFICATION PURSUANT TO 18 U.S.C. §1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

EXHIBIT 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. §1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the annual report of Oncolytics Biotech Inc. (the “Company”) on Form 20-F for the fiscal year ended December 31, 2023, as filed with the Securities and Exchange Commission on the date here of (the “Report”), I, Kirk Look, Chief Financial Officer of the Com

DESCRIPTION OF RIGHTS OF SECURITIES REGISTERED UNDER SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934

EXHIBIT 2.1 DESCRIPTION OF RIGHTS OF SECURITIES REGISTERED UNDER SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Our authorized capital consists of an unlimited number of Common Shares. The following is a summary of the provisions attached to our Common Shares: The holders of our Common Shares are entitled to one vote per share at meetings of shareholders, to receive such dividends as declared b

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

EXHIBIT 15.2 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in the following Registration Statements: 1.Form S-8 nos. 333-171625 and 333-205708 2.Form F-10 no. 333-265510 of Oncolytics Biotech Inc. (the “Company”) of our reports dated March 7, 2024, with respect to the consolidated statements of financial position as at December 31, 2023 and D

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For fiscal year ended December 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 19

Date: March 12, 2024 /s/Matthew Coffey Dr. Matthew Coffey, PhD, MBA Chief Executive Officer Principal Executive Officer

EXHIBIT 12.1 CERTIFICATION I, Matthew Coffey, certify that: 1.I have reviewed this annual report on Form 20-F of Oncolytics Biotech Inc.; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect

LIST OF SUBSIDIARIES Name Jurisdiction Oncolytics Biotech (Barbados) Inc. Barbados Oncolytics Biotech (US) Inc. Delaware

EXHIBIT 8.0 LIST OF SUBSIDIARIES 2023 Name Jurisdiction Oncolytics Biotech (Barbados) Inc. Barbados Oncolytics Biotech (US) Inc. Delaware

EMPLOYMENT AGREEMENT

EXHIBIT 4.12 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (“Agreement”), effective September 1, 2020 (“Effective Date”), is made between Oncolytics Biotech (U.S.), Inc., (“Employer” or the “Company”), and Amy Goodowitz Levin (“Employee”). Employee and the Company are sometimes referred to herein as the “Parties.” RECITALS A.Employer is in the business (the “Business”) of developing pharmaceutica

Date: March 12, 2024 /s/Kirk Look Kirk Look, CA Chief Financial Officer Principal Accounting and Financial Officer

EXHIBIT 12.2 CERTIFICATION I, Kirk Look, certify that: 1. I have reviewed this annual report on Form 20-F of Oncolytics Biotech Inc.; 1.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to

AMENDING AGREEMENT # 1

EXHIBIT 4.13 AMENDING AGREEMENT # 1 THIS AMENDING AGREEMENT made effective as of the 1st day of January, 2023. BETWEEN: Oncolytics Biotech (U.S.), Inc., ("OBUS") - and - Amy Goodowitz Levin (the "Employee") WHEREAS the Employee is an employee of OBUS whose terms of employment are set forth in the Employment Agreement dated effective September 1, 2020, (the “Employment Agreement”); AND WHEREAS OBUS

Oncolytics Biotech Inc. INCENTIVE COMPENSATION RECOVERY POLICY

EXHIBIT 97.1 Oncolytics Biotech Inc. INCENTIVE COMPENSATION RECOVERY POLICY 1.Introduction. The Board of Directors (the “Board”) of Oncolytics Biotech Inc. (the “Company”) believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company's compensation philosophy. The Board has

CERTIFICATION PURSUANT TO 18 U.S.C. §1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

EXHIBIT 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. §1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the annual report of Oncolytics Biotech Inc. (the “Company”) on Form 20-F for the fiscal year ended December 31, 2023, as filed with the Securities and Exchange Commission on the date here of (the “Report”), I, Matthew Coffey, Chief Executive Officer of th

ONCOLYTICS BIOTECH INC. CORPORATE TRADING POLICY Table of Contents

EXHIBIT 16.1 ONCOLYTICS BIOTECH INC. Corporate Trading Policy Reviewed and approved by the Board March 5, 2020 EXHIBIT 16.1 ONCOLYTICS BIOTECH INC. CORPORATE TRADING POLICY Table of Contents 1.CONFIDENTIAL INFORMATION AND TRADING POLICY ................................... 1 (A) WHO IS SUBJECT TO THIS POLICY? ..........................................................................................

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March 2024 Commission File Number 001-38512 Oncolytics Biote

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March 2024 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executive

Oncolytics Biotech® Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights Pelareorep advancing to a registration-enabling study in 2024 in pancreatic cancer and expands pancreatic potential with new GOBLET cohort in c

Oncolytics Biotech® Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights Pelareorep advancing to a registration-enabling study in 2024 in pancreatic cancer and expands pancreatic potential with new GOBLET cohort in combination with mFOLFIRINOX Impressive objective response rate in GOBLET study anal carcinoma cohort supports enrollment expansion Expecting to report overall survival data from BRACELET-1 breast cancer study in 2024 Cash position of $34.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March 2024 Commission File Number 001-38512 Oncolytics Biote

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March 2024 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executive

Oncolytics Biotech® Files Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCAN US$5M grant supports study of pelareorep in combination with modified FOLFIRINOX +/- atezolizumab Testing with the most common therapies could fac

Oncolytics Biotech® Files Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCAN US$5M grant supports study of pelareorep in combination with modified FOLFIRINOX +/- atezolizumab Testing with the most common therapies could facilitate broad use of pelareorep in pancreatic cancer patients SAN DIEGO, CA and CALGARY, AB, March 5, 2024 - Oncolytics Biotech® Inc.

Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights Conference call and webcast to take place on Thursday, March 7, 2024, at 4:30 p.m. ET

Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights Conference call and webcast to take place on Thursday, March 7, 2024, at 4:30 p.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March 2024 Commission File Number 001-38512 Oncolytics Biote

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March 2024 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executive

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2024 Commission File Number 001-38512 Oncolytics Bi

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2024 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal execut

Oncolytics Biotech® Announces Presentation at the Cancer Advocacy Group of Louisiana’s 3rd Annual NeauxCancer Conference

Oncolytics Biotech® Announces Presentation at the Cancer Advocacy Group of Louisiana’s 3rd Annual NeauxCancer Conference SAN DIEGO, CA and CALGARY, AB, February 28, 2024 - Oncolytics Biotech® Inc.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2024 Commission File Number 001-38512 Oncolytics Bi

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2024 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal execut

Oncolytics Biotech® Initiates Enrollment Expansion of GOBLET Anal Cancer Cohort Successful Stage 1 data showed a near tripling of Objective Response Rate compared to checkpoint inhibitor monotherapy, including a Complete Response, and supports expans

Oncolytics Biotech® Initiates Enrollment Expansion of GOBLET Anal Cancer Cohort Successful Stage 1 data showed a near tripling of Objective Response Rate compared to checkpoint inhibitor monotherapy, including a Complete Response, and supports expansion SAN DIEGO, CA and CALGARY, AB, February 14, 2024 - Oncolytics Biotech® Inc.

Oncolytics Biotech® Appoints Patricia S. Andrews to its Board of Directors

Oncolytics Biotech® Appoints Patricia S. Andrews to its Board of Directors SAN DIEGO, CA and CALGARY, AB, January 9, 2024 - Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced the appointment of Patricia S. Andrews to its Board of Directors (the “Board”). “I am pleased to welcome Pat Andrews to our Board of Directors,

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of January 2024 Commission File Number 001-38512 Oncolytics Bio

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of January 2024 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executi

Oncolytics Biotech® Recaps 2023 Accomplishments, Provides Outlook for 2024

Oncolytics Biotech® Recaps 2023 Accomplishments, Provides Outlook for 2024 SAN DIEGO, CA and CALGARY, AB, January 4, 2024 - Oncolytics Biotech® Inc.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of January 2024 Commission File Number 001-38512 Oncolytics Bio

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of January 2024 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executi

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2023 Commission File Number 001-38512 Oncolytics Bi

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2023 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal execut

Oncolytics Biotech® and SOLTI Present Positive Translational Data at SABCS Pelareorep induced prominent expansion of pre-existing Tumor Infiltrating Lymphocytes (TILs) in the blood and new TILs in the tumor Data highlights the association between the

Oncolytics Biotech® and SOLTI Present Positive Translational Data at SABCS Pelareorep induced prominent expansion of pre-existing Tumor Infiltrating Lymphocytes (TILs) in the blood and new TILs in the tumor Data highlights the association between the expansion of existing TILs in the blood and decreased tumor size Results affirm pelareorep’s role as an immunotherapy SAN DIEGO, CA and CALGARY, AB, December 7, 2023 - Oncolytics Biotech® Inc.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2023 Commission File Number 001-38512 Oncolytics Bi

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2023 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal execut

Oncolytics Provides Update on Pancreatic Cancer Program for Pelareorep Updated plan follows PanCAN’s strategic re-evaluation of the Precision PromiseSM Program PanCAN US$5 million grant provides support for new GOBLET mFOLFIRINOX arm to proceed as pl

Oncolytics Provides Update on Pancreatic Cancer Program for Pelareorep Updated plan follows PanCAN’s strategic re-evaluation of the Precision PromiseSM Program PanCAN US$5 million grant provides support for new GOBLET mFOLFIRINOX arm to proceed as planned New Phase 3 strategy provides significant value-creation opportunities SAN DIEGO, CA, and CALGARY, AB, November 9, 2023 - Oncolytics Biotech® Inc.

Oncolytics Announces the Anal Cancer Cohort of the GOBLET Phase 1/2 Study of Pelareorep and Atezolizumab Has Met the Success Criteria for Efficacy Pelareorep-atezolizumab combination data exceeds historical control trials with a 37.5% objective respo

Oncolytics Announces the Anal Cancer Cohort of the GOBLET Phase 1/2 Study of Pelareorep and Atezolizumab Has Met the Success Criteria for Efficacy Pelareorep-atezolizumab combination data exceeds historical control trials with a 37.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2023 Commission File Number 001-38512 Oncolytics Bi

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2023 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal execut

Oncolytics Biotech® Reports Third Quarter 2023 Financial Results and Operational Highlights Phase 1/2 survival data from GOBLET pancreatic cancer cohort demonstrates improvements over historical control trials Award and grant funding from Pancreatic

Oncolytics Biotech® Reports Third Quarter 2023 Financial Results and Operational Highlights Phase 1/2 survival data from GOBLET pancreatic cancer cohort demonstrates improvements over historical control trials Award and grant funding from Pancreatic Cancer Action Network (PanCAN) provides financial boost and will enable further evaluation of pelareorep in pancreatic cancer Cash position stands at $40.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2023 Commission File Number 001-38512 Oncolytics Bi

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2023 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal execut

Oncolytics Biotech® and SOLTI Present Further Positive Pelareorep Translational Data at SITC Novel imaging mass cytometry (IMC) technology enables a closer look at tumor microenvironment post-pelareorep/atezolizumab/letrozole treatment Affirms pelare

Oncolytics Biotech® and SOLTI Present Further Positive Pelareorep Translational Data at SITC Novel imaging mass cytometry (IMC) technology enables a closer look at tumor microenvironment post-pelareorep/atezolizumab/letrozole treatment Affirms pelareorep’s ability to increase PD-L1 positive cells and T cell infiltration in the tumor microenvironment Data will support conduct of registrational program for pelareorep SAN DIEGO, CA and CALGARY, AB, November 3, 2023 - Oncolytics Biotech® Inc.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2023 Commission File Number 001-38512 Oncolytics Bi

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2023 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal execut

FORM 52‑109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE

FORM 52‑109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Matthew Coffey, President and CEO of Oncolytics Biotech Inc.

MANAGEMENT'S DISCUSSION & ANALYSIS September 30, 2023

MANAGEMENT'S DISCUSSION & ANALYSIS September 30, 2023 November 2, 2023 MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This discussion and analysis should be read in conjunction with our unaudited condensed interim consolidated financial statements and notes thereto as at and for the three and nine months ended September 30, 2023, and should also be read in conjunction with the audited consolidated financial statements and Management's Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) contained in our annual report for the year ended December 31, 2022.

FORM 52‑109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE

FORM 52‑109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Kirk Look, CFO of Oncolytics Biotech Inc.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2023 Commission File Number 001-38512 Oncolytics Bi

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2023 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant’s name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal execut

ONCOLYTICS BIOTECH INC. CONDENSED INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (in thousands of Canadian dollars, except share amounts) As at September 30, 2023 December 31, 2022 Assets Current assets Cash and cash equivalents (note 4) $ 39,

Condensed Interim Consolidated Financial Statements (unaudited) Oncolytics Biotech® Inc.

Oncolytics Presents Positive Updated Pancreatic Cancer Data from GOBLET Phase 1/2 Study at ESMO 7.2 months mPFS and 10.6 months interim median OS surpass historical outcomes by ≥ 25% T-cell expansion data correlate with tumor response, providing impo

Oncolytics Presents Positive Updated Pancreatic Cancer Data from GOBLET Phase 1/2 Study at ESMO 7.

Oncolytics Achieves Success Criteria for Efficacy in the Third-Line Colorectal Cancer Cohort of the GOBLET Study Results met efficacy criteria for enrollment expansion and provide support for pelareorep’s mechanism of action

Oncolytics Achieves Success Criteria for Efficacy in the Third-Line Colorectal Cancer Cohort of the GOBLET Study Results met efficacy criteria for enrollment expansion and provide support for pelareorep’s mechanism of action SAN DIEGO, CA, and CALGARY, AB, October 23, 2023 - Oncolytics Biotech® Inc.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of October 2023 Commission File Number 001-38512 Oncolytics Bio

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of October 2023 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executi

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of October 2023 Commission File Number 001-38512 Oncolytics Bio

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of October 2023 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executi

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of October 2023 Commission File Number 001-38512 Oncolytics Bio

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of October 2023 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executi

Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational Highlights Conference call and webcast to take place on Friday, November 3, 2023, at 8:30 a.m. ET

Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational Highlights Conference call and webcast to take place on Friday, November 3, 2023, at 8:30 a.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of October 2023 Commission File Number 001-38512 Oncolytics Bio

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of October 2023 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executi

Oncolytics Biotech® To Present Two Posters on the Pelareorep-Based GOBLET Study at ESMO 2023 Preliminary updated PDAC data show 6-month overall survival rate of 82% Results from pelareorep combination in mCRC met the Stage 1 success criteria

Oncolytics Biotech® To Present Two Posters on the Pelareorep-Based GOBLET Study at ESMO 2023 Preliminary updated PDAC data show 6-month overall survival rate of 82% Results from pelareorep combination in mCRC met the Stage 1 success criteria SAN DIEGO, CA and CALGARY, AB, October 16, 2023 - Oncolytics Biotech® Inc.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2023 Commission File Number 001-38512 Oncolytics B

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2023 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal execu

THE PANCREATIC CANCER ACTION NETWORK SELECTS ONCOLYTICS BIOTECH® INC. TO RECEIVE $5 MILLION THERAPEUTIC ACCELERATOR AWARD TO DEVELOP LEADING-EDGE TREATMENTS Innovative Multimillion-Dollar Grant Was Created in 2022 to Drive Biopharma Industry to Speed

THE PANCREATIC CANCER ACTION NETWORK SELECTS ONCOLYTICS BIOTECH® INC. TO RECEIVE $5 MILLION THERAPEUTIC ACCELERATOR AWARD TO DEVELOP LEADING-EDGE TREATMENTS Innovative Multimillion-Dollar Grant Was Created in 2022 to Drive Biopharma Industry to Speed Development of Pancreatic Cancer Therapies BOSTON, MA., San Diego, CA., and Calgary, AB. – (September 26, 2023) – In an effort to continue accelerati

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2023 Commission File Number 001-38512 Oncolytics B

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2023 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal execu

Oncolytics Biotech® Announces Fireside Chat at the Cantor Global Healthcare Conference

Oncolytics Biotech® Announces Fireside Chat at the Cantor Global Healthcare Conference SAN DIEGO, CA and CALGARY, AB, September 19, 2023 - Oncolytics Biotech® Inc.

Oncolytics Biotech® to Participate in a Fireside Chat at the H.C. Wainwright 25th Annual Global Investment Conference

Oncolytics Biotech® to Participate in a Fireside Chat at the H.C. Wainwright 25th Annual Global Investment Conference SAN DIEGO, CA and CALGARY, AB, September 6, 2023 - Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that Chief Executive Officer Dr. Matt Coffey will participate in a fireside chat at the H.C. Wainwright 25th Annual Global Investment Conference, which is taking pl

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2023 Commission File Number 001-38512 Oncolytics B

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2023 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal execu

MANAGEMENT'S DISCUSSION & ANALYSIS June 30, 2023

MANAGEMENT'S DISCUSSION & ANALYSIS June 30, 2023 August 13, 2023 MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This discussion and analysis should be read in conjunction with our unaudited condensed interim consolidated financial statements and notes thereto as at and for the three and six months ended June 30, 2023, and should also be read in conjunction with the audited consolidated financial statements and Management's Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) contained in our annual report for the year ended December 31, 2022.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2023 Commission File Number 001-38512 Oncolytics Biot

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2023 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant’s name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executiv

FORM 52‑109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE

FORM 52‑109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Matthew Coffey, President and CEO of Oncolytics Biotech Inc.

FORM 52‑109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE

FORM 52‑109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Kirk Look, CFO of Oncolytics Biotech Inc.

ONCOLYTICS BIOTECH INC. CONDENSED INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (in thousands of Canadian dollars, except share amounts) As at June 30, 2023 December 31, 2022 Assets Current assets Cash and cash equivalents (note 4) $ 17,520 $

Condensed Interim Consolidated Financial Statements (unaudited) Oncolytics Biotech® Inc.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2023 Commission File Number 001-38512 Oncolytics Biot

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2023 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executiv

Oncolytics Biotech® Reports Second Quarter 2023 Financial Results and Operational Highlights Phase 2 data from randomized BRACELET-1 trial in HR+/HER2- metastatic breast cancer showed a near tripling of confirmed ORR, >50% improvement in PFS, and 71%

Oncolytics Biotech® Reports Second Quarter 2023 Financial Results and Operational Highlights Phase 2 data from randomized BRACELET-1 trial in HR+/HER2- metastatic breast cancer showed a near tripling of confirmed ORR, >50% improvement in PFS, and 71% reduction in risk of disease progression Pelareorep selected for inclusion in the Precision PromiseSM phase 3 platform trial in pancreatic cancer, designed to accelerate registration path and reduce by ~50% phase 3 costs compared to traditional trial $24.

Oncolytics Biotech® to Host Conference Call to Discuss Second Quarter Financial Results and Recent Operational Highlights Conference call and webcast to take place on Monday, August 14, 2023, at 8:30 a.m. ET

Oncolytics Biotech® to Host Conference Call to Discuss Second Quarter Financial Results and Recent Operational Highlights Conference call and webcast to take place on Monday, August 14, 2023, at 8:30 a.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2023 Commission File Number 001-38512 Oncolytics Biot

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2023 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executiv

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2023 Commission File Number 001-38512 Oncolytics Biot

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2023 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executiv

Oncolytics Biotech® to Participate in a Fireside Chat at Canaccord Genuity’s 43rd Annual Growth Conference

Oncolytics Biotech® to Participate in a Fireside Chat at Canaccord Genuity’s 43rd Annual Growth Conference SAN DIEGO, CA and CALGARY, AB, August 4, 2023 - Oncolytics Biotech® Inc.

Oncolytics Biotech’s® Pelareorep Selected for Inclusion in Precision PromiseSM Pivotal Phase 3 Platform Trial Adaptive clinical trial designed to accelerate registration pathways for pancreatic cancer therapies and expected to reduce cost of a Phase

Oncolytics Biotech’s® Pelareorep Selected for Inclusion in Precision PromiseSM Pivotal Phase 3 Platform Trial Adaptive clinical trial designed to accelerate registration pathways for pancreatic cancer therapies and expected to reduce cost of a Phase 3 study for pelareorep by ~50% compared to a traditional trial If successful, new clinical study expected to support approval of pelareorep in combina

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2023 Commission File Number 001-38512 Oncolytics Biotec

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2023 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executive

Oncolytics Biotech® Announces Updated Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial that Show Pelareorep Driving Robust Increases in Progression-Free Survival and Confirmed Overall Response Rate Pelareorep-paclitaxel combinat

Oncolytics Biotech® Announces Updated Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial that Show Pelareorep Driving Robust Increases in Progression-Free Survival and Confirmed Overall Response Rate Pelareorep-paclitaxel combination reduced risk of disease progression by 71% (hazard ratio of 0.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2023 Commission File Number 001-38512 Oncolytics Biotec

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2023 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executive

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2023 Commission File Number 001-38512 Oncolytics Biotech

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2023 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executive o

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2023 Commission File Number 001-38512 Oncolytics Biotech

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2023 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executive o

Oncolytics Biotech® Announces Positive Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial Demonstrating Pelareorep Drives ≥50% Improvements in ORR and mPFS in an ASCO Annual Meeting Abstract 31% week-16 overall response rate and 9

Oncolytics Biotech® Announces Positive Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial Demonstrating Pelareorep Drives ≥50% Improvements in ORR and mPFS in an ASCO Annual Meeting Abstract 31% week-16 overall response rate and 9.

Oncolytics Biotech® to Host Key Opinion Leader Webinar on Data from the Randomized BRACELET-1 Trial in HR+/HER2- Metastatic Breast Cancer Being Presented at the Upcoming ASCO Annual Meeting Key opinion leader webinar to take place on June 5, 2023 at

Oncolytics Biotech® to Host Key Opinion Leader Webinar on Data from the Randomized BRACELET-1 Trial in HR+/HER2- Metastatic Breast Cancer Being Presented at the Upcoming ASCO Annual Meeting Key opinion leader webinar to take place on June 5, 2023 at 8:00 a.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of May, 2023. Commission File Number 001-38512 Oncolytics Bi

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of May, 2023. Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant’s name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal execut

ONCOLYTICS BIOTECH INC. ANNUAL GENERAL MEETING OF SHAREHOLDERS MAY 9, 2023 VOTING RESULTS

ONCOLYTICS BIOTECH INC. ANNUAL GENERAL MEETING OF SHAREHOLDERS MAY 9, 2023 VOTING RESULTS Resolution #1: By way of electronic Ballot, the Chairman declared that the shareholders ratified the resolution to fix the number of directors of the Corporation for the ensuing year at seven (7). For: 10,763,141 87.42% Against: 1,548,656 12.58% Total: 12,311,797 100% Resolution #2: By way of electronic Ballo

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2023 Commission File Number 001-38512 Oncolytics Biotech

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2023 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executive o

Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders

EX-99.1 2 agmvotingresults2023.htm EX-99.1 Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders SAN DIEGO, CA and CALGARY, AB, May 10, 2023 - Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), today announced the voting results from its Annual General Meeting (AGM) of Shareholders held on Tuesday, May 9, 2023. A total of 44% of the issued and outstanding co

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2023 Commission File Number 001-38512 Oncolytics Biotech

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2023 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant’s name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executive o

FORM 52‑109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE

FORM 52‑109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Kirk Look, CFO of Oncolytics Biotech Inc.

Oncolytics Biotech® Reports First Quarter 2023 Financial Results and Operational Highlights Randomized phase 2 data from BRACELET-1 trial in HR+/HER2- metastatic breast cancer to be shared in an oral presentation at the American Society of Clinical O

Oncolytics Biotech® Reports First Quarter 2023 Financial Results and Operational Highlights Randomized phase 2 data from BRACELET-1 trial in HR+/HER2- metastatic breast cancer to be shared in an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting Guidance on the registration paths for pelareorep in HR+/HER2- metastatic breast and first-line pancreatic cancer expected in H2 2023 $29.

MANAGEMENT'S DISCUSSION & ANALYSIS March 31, 2023

MANAGEMENT'S DISCUSSION & ANALYSIS March 31, 2023 May 4, 2023 MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This discussion and analysis should be read in conjunction with our unaudited condensed interim consolidated financial statements and notes thereto as at and for the three months ended March 31, 2023, and should also be read in conjunction with the audited consolidated financial statements and Management's Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) contained in our annual report for the year ended December 31, 2022.

ONCOLYTICS BIOTECH INC. CONDENSED INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (in thousands of Canadian dollars, except share amounts) As at March 31, 2023 December 31, 2022 Assets Current assets Cash and cash equivalents (note 4) $ 15,872

Condensed Interim Consolidated Financial Statements (unaudited) Oncolytics Biotech® Inc.

FORM 52‑109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE

FORM 52‑109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Matthew Coffey, President and CEO of Oncolytics Biotech Inc.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2023 Commission File Number 001-38512 Oncolytics Biotech

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2023 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executive o

Oncolytics Biotech® Announces Upcoming Oral Presentation on Randomized BRACELET-1 Trial in HR+/HER2- Metastatic Breast Cancer at the ASCO Annual Meeting Oral presentation on BRACELET-1 to take place on June 3, 2023

Oncolytics Biotech® Announces Upcoming Oral Presentation on Randomized BRACELET-1 Trial in HR+/HER2- Metastatic Breast Cancer at the ASCO Annual Meeting Oral presentation on BRACELET-1 to take place on June 3, 2023 SAN DIEGO, CA and CALGARY, AB, April 26, 2023 – Oncolytics Biotech® Inc.